Cayuga Biotech secures $8M in Seed funding to advance their novel therapeutic, CAY001, for life-threatening hemorrhage. Led by Wharton Alumni Angels, this funding includes a $3M award from the DHA.
Amount Raised
$8 Million
Round Type
Seed
New YorkBiotechnologyHealth CareTherapeuticsInvestors
Description
Cayuga Biotech, Inc announced the closing of $8M seed funding to develop CAY001, aimed at addressing life-threatening hemorrhage. The funding round was led by Wharton Alumni Angels with participation from multiple investors and includes a $3M award from the DHA. This capital will support the advancement of Phase 1 clinical trials for their novel therapeutic. The treatment aims to generate human proof-of-concept data in 2026.
Who else raised in Therapeutics and Biotechnology around the same time
Companies in the same sectors as Cayuga Biotech that raised within 45 days of this round, from Fundz verified event records.
- Corxel Pharmaceuticals raised $287M (Series D) on January 22, 2026.
- ImmunoMet Therapeutics raised $842K on January 21, 2026.
- Os Therapies raised $3.5M on January 14, 2026.
- Vivere Oncotherapies raised $10M (Funding Round) on January 13, 2026.
- Tessera Defense & Homeland Security Inc. raised $3.3M on January 13, 2026.
- Aurora Therapeutics raised $16M (Seed) on January 9, 2026.
Who to call at Cayuga Biotech, and when
A new round usually means Cayuga Biotech is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Cayuga Biotech raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Cayuga Biotech, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Cayuga Biotech. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Cayuga Biotech raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Cayuga Biotech raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.